medigraphic.com

2018, Number 6

<< Back Next >>

Cir Cir 2018; 86 (6)

Congenital-neonatal hydrocephalus: therapeutic alternatives to derivation. A look at cell therapy

Uparela-Reyes MJ, Narváez-Rojas AR, Quintana-Pájaro L, Ramos-Villegas Y, Moscote-Salazar LR

Language: Spanish
References: 40
Page: 575-582
PDF size: 181.44 Kb.


ABSTRACT

Introduction: Fetal hydrocephalus, perinatal and neonatal represents a major therapeutic challenge and often has with poor neurological prognosis, due to its heterogeneous aetiology, including neurodevelopmental disorders. Objective: To make a collection of advances in cell therapy as a proposal that can extend the spectrum of treatment in congenita-neonatal hydrocephalus. Development: Therapeutic interventions available at present as the ventricle-peritoneal shunt and third ventriculostomy, are insufficient to fully resolve the hydrocephalus and to prevent or reverse the associated neurological damage. This is why what has emerged the need for new therapeutic alternatives based on the knowledge of physiopathological mechanisms involved in the development of this condition. In particular, cell therapy with neural stem cells and mesenchymal stem cells has proven in animal studies and preclinical studies with humans, efficiently and safely to prevent hydrocephalus originated from the disruption of the ventricular zone and secondary to intraventricular hemorrhage, with the consequent prevention of neurological sequelae sensorimotor and cognitive. Conclusions: So far, we do not have an efficient treatment that offers quality of life to patients with hydrocephalus, and that alternative therapy to be effective.


REFERENCES

  1. Oi S, Inagaki T, Shinoda M, Takahashi S, Ono S, Date I, et al. Guideline for management and treatment of fetal and congenital hydrocephalus: Center of Excellence — Fetal and Congenital Hydrocephalus Top 10 Japan Guideline 2011. Child’s Nerv Syst. 2011;27:1563-70.

  2. Yamasaki M, Nonaka M, Bamba Y, Teramoto C, Ban C, Pooh RK. Diagnosis, treatment, and long-term outcomes of fetal hydrocephalus. Semin Fetal Neonatal Med. 2012;17:330-5.

  3. McAllister JP. Pathophysiology of congenital and neonatal hydrocephalus. Semin Fetal Neonatal Med. 2012;17:285-94.

  4. Rekate HL. Selecting patients for endoscopic third ventriculostomy. Neurosurg Clin N Am. 2004;15:39-49.

  5. Nishiyama K, Mori H, Tanaka R. Changes in cerebrospinal fluid hydrodynamics following endoscopic third ventriculostomy for shunt-dependent noncommunicating hydrocephalus. J Neurosurg. 2003;98:1027-31.

  6. Guerra M, Blázquez JL, Rodríguez EM. Blood-brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow. Fluids Barriers CNS. 2017;14:19.

  7. Browd SR, Ragel BT, Gottfried ON, Kestle JRW. Failure of cerebrospinal fluid shunts: part I: obstruction and mechanical failure. Pediatr Neurol. 2006;34:83-92.

  8. Domínguez-Pinos MD, Páez P, Jiménez A-J, Weil B, Arráez M-A, Pérez- Fígares J-M, et al. Ependymal denudation and alterations of the subventricular zone occur in human fetuses with a moderate communicating hydrocephalus. J Neuropathol Exp Neurol. 2005;64:595-604.

  9. Wagner C, Batiz LF, Rodríguez S, Jiménez AJ, Páez P, Tomé M, et al. Cellular mechanisms involved in the stenosis and obliteration of the cerebral aqueduct of hyh mutant mice developing congenital hydrocephalus. J Neuropathol Exp Neurol. 2003;62:1019-40.

  10. Rodríguez EM, Guerra MM. Neural stem cells and fetal-onset hydrocephalus. Pediatr Neurosurg. 2017;52:446-61.

  11. Guerra MM, Henzi R, Ortloff A, Lichtin N, Vío K, Jiménez AJ, et al. Cell junction pathology of neural stem cells is associated with ventricular zone disruption, hydrocephalus, and abnormal neurogenesis. J Neuropathol Exp Neurol. 2015;74:653-71.

  12. Shibasaki T, Tokunaga A, Sakamoto R, Sagara H, Noguchi S, Sasaoka T, et al. PTB deficiency causes the loss of adherens junctions in the dorsal telencephalon and leads to lethal hydrocephalus. Cereb Cortex. 2013;23:1824-35.

  13. Rašin M-R, Gazula V-R, Breunig JJ, Kwan KY, Johnson MB, Liu-Chen S, et al. Numb and Numbl are required for maintenance of cadherin-based adhesion and polarity of neural progenitors. Nat Neurosci. 2007; 10:819-27.

  14. Oliver C, González CA, Alvial G, Flores CA, Rodríguez EM, Bátiz LF. Disruption of CDH2/N-cadherin-based adherens junctions leads to apoptosis of ependymal cells and denudation of brain ventricular walls. J Neuropathol Exp Neurol. 2013;72:846-60.

  15. Guerra M, Sival D, Jiménez A, Domínguez Pinos M, den Dunnen W, Bátiz L, et al. Defects in cell-cell junctions lead to neuroepithelial/ependymal denudation in the telencephalon of human hydrocephalic foetuses. Cerebrospinal Fluid Res. 2010;7(Suppl 1):S56.

  16. Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res. 2010;67:1-8.

  17. Ahn SY, Chang YS, Park WS. Mesenchymal stem cells transplantation for neuroprotection in preterm infants with severe intraventricular hemorrhage. Korean J Pediatr. 2014;57:251.

  18. Fang H, Wang P-F, Zhou Y, Wang Y-C, Yang Q-W. Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury. J Neuroinflammation. 2013;10:794.

  19. Park WS, Ahn SY, Sung SI, Ahn J-Y, Chang YS. Mesenchymal stem cells: the magic cure for intraventricular hemorrhage? Cell Transplant. 2017;26:439-48.

  20. Lindvall O, Björklund A. Cell therapeutics in Parkinson’s disease. Neurotherapeutics. 2011;8:539-48.

  21. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson’s disease. BMC Med. 2012;10:1.

  22. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441:1094-6.

  23. Bjorklund A, Kordower JH. Cell therapy for Parkinson’s disease: what next? Mov Disord. 2013;28:110-5.

  24. Yuan Q, Bu X-Y, Yan Z-Y, Liu X-Z, Wei Z-Y, Ma C-X, et al. Combination of endogenous neural stem cell mobilization and lithium chloride treatment for hydrocephalus following intraventricular hemorrhage. Exp Ther Med. 2016;12:3275-81.

  25. Guerra M. Neural stem cells: are they the hope of a better life for patients with fetal-onset hydrocephalus? Fluids Barriers CNS. 2014;11:7.

  26. Cacci E, Villa A, Parmar M, Cavallaro M, Mandahl N, Lindvall O, et al. Generation of human cortical neurons from a new immortal fetal neural stem cell line. Exp Cell Res. 2007;313:588-601.

  27. Monni E, Cusulin C, Cavallaro M, Lindvall O, Kokaia Z. Human fetal striatum-derived neural stem (NS) cells differentiate to mature neurons in vitro and in vivo. Curr Stem Cell Res Ther. 2014;9:338-46.

  28. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res. 2015;2015:394917.

  29. Ahn SY, Chang YS, Sung DK, Sung SI, Yoo HS, Lee JH, et al. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke. 2013;44:497-504.

  30. Ahn SY, Chang YS, Sung DK, Sung SI, Ahn J-Y, Park WS. Pivotal role of brain-derived neurotrophic factor secreted by mesenchymal stem cells in severe intraventricular hemorrhage in newborn rats. Cell Transplant. 2017;26:145-56.

  31. Park WS, Sung SI, Ahn SY, Sung DK, Im GH, Yoo HS, et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplant. 2016;25:1131-44.

  32. Kim ES, Ahn SY, Im GH, Sung DK, Park YR, Choi SH, et al. Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res. 2012;72:277-84.

  33. Ahn SY, Chang YS, Sung DK, Sung SI, Yoo HS, Im GH, et al. Optimal route for mesenchymal stem cells transplantation after severe intraventricular hemorrhage in newborn rats. PLoS One. 2015;10:e0132919.

  34. Fang B, Wang H, Sun X-J, Li X-Q, Ai C-Y, Tan W-F, et al. Intrathecal transplantation of bone marrow stromal cells attenuates blood-spinal cord barrier disruption induced by spinal cord ischemia-reperfusion injury in rabbits. J Vasc Surg. 2013;58:1043-52.

  35. Donega V, Nijboer CH, van Velthoven CTJ, Youssef SA, de Bruin A, van Bel F, et al. Assessment of long-term safety and efficacy of intranasal mesenchymal stem cell treatment for neonatal brain injury in the mouse. Pediatr Res. 2015;78 520-6.

  36. Donega V, van Velthoven CTJ, Nijboer CH, van Bel F, Kas MJH, Kavelaars A, et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One. 2013;8:e51253.

  37. Ahn SY, Chang YS, Park WS. Stem cells for neonatal brain disorders. Neonatology. 2016;109:377-83.

  38. van Velthoven CTJ, Kavelaars A, van Bel F, Heijnen CJ. Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain. Brain Behav Immun. 2011;25:1342-8.

  39. Chang YS, Ahn SY, Sung S, Park WS. Stem cell therapy for neonatal disorders: prospects and challenges. Yonsei Med J. 2017;58:266-71.

  40. Lancaster MA, Renner M, Martin C-A, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373-9.




2020     |     www.medigraphic.com